Laurus Labs has received the Establishment Inspection Report (EIR) from US Food and Drug Administration (USFDA) for its Finished Dosage Formulations (FDF) & Active Pharmaceutical Ingredients (API) manufacturing plant, Unit 2, located at Atchutapuram, Vishakhapatnam, for the inspection completed in May 2017.
Besides, Unit 2 (FDF) has also completed the BGV Hamburg (German Regulatory Authority) inspection and Units 1 & 3 located at Parawada, Visakhapatnam have completed WHO (Geneva) inspection successfully during this month with no critical or major observations.
Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of Active Pharmaceutical Ingredients (APIs) for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.
